Home Healthcare Pharmaceuticals Radioligand Therapy Market

Radioligand Therapy Market Size, Share & Trends Analysis Report By Isotope (Lutetium-177 (Lu-177), Actinium-225 (Ac-225), Iodine-131 (I-131), Other Isotopes), By Target (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor), By Indication (Prostate Cancer, Neuroendocrine Tumours (NETs), Others), By End-User (Hospitals, Ambulatory Surgical Centers, Cancer Treatment Centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Debashree B | Format: | Report Code: SR1746DR | Pages: 155
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Radioligand Therapy Market, By Isotope 2022-2034 (USD MILLION/ Units)
    1. Lutetium-177 (Lu-177)
    2. Actinium-225 (Ac-225)
    3. Iodine-131 (I-131)
    4. Other Isotopes
  2. Radioligand Therapy Market, By Target 2022-2034 (USD MILLION/ Units)
    1. Prostate-Specific Membrane Antigen
    2. Ki 67 Expression and Grading
    3. Cytochrome P450 17A1 Inhibitor
  3. Radioligand Therapy Market, By Indication 2022-2034 (USD MILLION/ Units)
    1. Prostate Cancer
    2. Neuroendocrine Tumours (NETs)
    3. Others
  4. Radioligand Therapy Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Ambulatory Surgical Centers
    3. Cancer Treatment Centers
    4. Others
  5. Regional Radioligand Therapy Market
    1. North America
      1. North America Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      2. North America Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      3. North America Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      4. North America Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
      5. U.S. Radioligand Therapy Market
        1. U.S. Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. U.S. Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. U.S. Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. U.S. Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      6. Canada Radioligand Therapy Market
        1. Canada Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Canada Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Canada Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Canada Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
    2. Europe
      1. Europe Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      2. Europe Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      3. Europe Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      4. Europe Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
      5. U.K. Radioligand Therapy Market
        1. U.K. Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. U.K. Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. U.K. Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. U.K. Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      6. Germany Radioligand Therapy Market
        1. Germany Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Germany Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Germany Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Germany Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      7. France Radioligand Therapy Market
        1. France Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. France Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. France Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. France Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      8. Spain Radioligand Therapy Market
        1. Spain Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Spain Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Spain Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Spain Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      9. Italy Radioligand Therapy Market
        1. Italy Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Italy Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Italy Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Italy Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      10. Russia Radioligand Therapy Market
        1. Russia Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Russia Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Russia Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Russia Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      11. Nordic Radioligand Therapy Market
        1. Nordic Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Nordic Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Nordic Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Nordic Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      12. Benelux Radioligand Therapy Market
        1. Benelux Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Benelux Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Benelux Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Benelux Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      13. Rest of Europe Radioligand Therapy Market
        1. Rest of Europe Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Rest of Europe Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Rest of Europe Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Rest of Europe Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
    3. APAC
      1. APAC Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      2. APAC Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      3. APAC Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      4. APAC Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
      5. China Radioligand Therapy Market
        1. China Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. China Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. China Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. China Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      6. Korea Radioligand Therapy Market
        1. Korea Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Korea Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Korea Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Korea Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      7. Japan Radioligand Therapy Market
        1. Japan Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Japan Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Japan Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Japan Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      8. India Radioligand Therapy Market
        1. India Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. India Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. India Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. India Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      9. Australia Radioligand Therapy Market
        1. Australia Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Australia Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Australia Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Australia Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      10. Taiwan Radioligand Therapy Market
        1. Taiwan Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Taiwan Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Taiwan Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Taiwan Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      11. South East Asia Radioligand Therapy Market
        1. South East Asia Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. South East Asia Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. South East Asia Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. South East Asia Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      12. Rest of Asia-Pacific Radioligand Therapy Market
        1. Rest of Asia-Pacific Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Rest of Asia-Pacific Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Rest of Asia-Pacific Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Rest of Asia-Pacific Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
    4. Middle East and Africa
      1. Middle East and Africa Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      2. Middle East and Africa Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      3. Middle East and Africa Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      4. Middle East and Africa Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
      5. UAE Radioligand Therapy Market
        1. UAE Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. UAE Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. UAE Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. UAE Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      6. Turkey Radioligand Therapy Market
        1. Turkey Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Turkey Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Turkey Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Turkey Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      7. Saudi Arabia Radioligand Therapy Market
        1. Saudi Arabia Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Saudi Arabia Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Saudi Arabia Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Saudi Arabia Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      8. South Africa Radioligand Therapy Market
        1. South Africa Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. South Africa Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. South Africa Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. South Africa Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      9. Egypt Radioligand Therapy Market
        1. Egypt Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Egypt Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Egypt Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Egypt Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      10. Nigeria Radioligand Therapy Market
        1. Nigeria Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Nigeria Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Nigeria Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Nigeria Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      11. Rest of MEA Radioligand Therapy Market
        1. Rest of MEA Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Rest of MEA Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Rest of MEA Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Rest of MEA Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
    5. LATAM
      1. LATAM Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
        1. Lutetium-177 (Lu-177)
        2. Actinium-225 (Ac-225)
        3. Iodine-131 (I-131)
        4. Other Isotopes
      2. LATAM Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
        1. Prostate-Specific Membrane Antigen
        2. Ki 67 Expression and Grading
        3. Cytochrome P450 17A1 Inhibitor
      3. LATAM Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Neuroendocrine Tumours (NETs)
        3. Others
      4. LATAM Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers
        3. Cancer Treatment Centers
        4. Others
      5. Brazil Radioligand Therapy Market
        1. Brazil Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Brazil Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Brazil Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Brazil Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      6. Mexico Radioligand Therapy Market
        1. Mexico Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Mexico Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Mexico Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Mexico Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      7. Argentina Radioligand Therapy Market
        1. Argentina Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Argentina Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Argentina Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Argentina Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      8. Chile Radioligand Therapy Market
        1. Chile Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Chile Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Chile Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Chile Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      9. Colombia Radioligand Therapy Market
        1. Colombia Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Colombia Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Colombia Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Colombia Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
      10. Rest of LATAM Radioligand Therapy Market
        1. Rest of LATAM Radioligand Therapy Market By Isotope 2022-2034 (USD MILLION/ Units)
          1. Lutetium-177 (Lu-177)
          2. Actinium-225 (Ac-225)
          3. Iodine-131 (I-131)
          4. Other Isotopes
        2. Rest of LATAM Radioligand Therapy Market By Target 2022-2034 (USD MILLION/ Units)
          1. Prostate-Specific Membrane Antigen
          2. Ki 67 Expression and Grading
          3. Cytochrome P450 17A1 Inhibitor
        3. Rest of LATAM Radioligand Therapy Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Prostate Cancer
          2. Neuroendocrine Tumours (NETs)
          3. Others
        4. Rest of LATAM Radioligand Therapy Market By End-User 2022-2034 (USD MILLION/ Units)
          1. Hospitals
          2. Ambulatory Surgical Centers
          3. Cancer Treatment Centers
          4. Others
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.